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Abstract: This study aimed at assessing the effects of diazoxon (DZO), a major 
metabolite of the insecticide diazinon (DZ), on key cytoskeletal proteins in differentiating 
N2a neuroblastoma cells. Initial experiments established that sub-lethal concentrations of 
1, 5 and 10 μM DZO produced profound inhibition of neurite outgrowth. Densitometric 
scanning of probed immunoblots of N2a cell lysates demonstrated that DZO had no 
effect on total β-tubulin levels. However, probing with a monoclonal antibody that 
recognised specifically the βIII-tubulin isotype revealed that 10 μM DZO induced a 
significant reduction in the levels of this particular form. Levels of polyglutamylated 
tubulin were not altered. Exposure to 10 μM DZO also decreased the expression of 
microtubule associated protein 1B (MAP 1B). However, DZO had no effect on the 
expression of MAP tau. DZO also failed to affect the levels neurofilament light (NFL) 
and neurofilament medium (NFM) chain levels. Indirect immunofluorescence 
demonstrated that the staining of neurites in treated cells was weaker than in the controls 
for βIII-tubulin. In conclusion, DZO disrupts the microtubule (MT) network affecting the 
expression and distribution of two specific MT proteins known to be important in 
neuritogenesis. DZO may contribute to the developmental neurotoxicity seen following 
exposure to DZ. 
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Introduction 
 
Organophosphorus esters (OPs) comprise the largest group of insecticides globally 
employed; however, due to their toxicity, they can cause damaging effects on mammals, 
birds and the environment in general. OPs can induce in adults a number of distinct 
neurotoxic effects [1], among which the most frequently encountered is acute 
neurotoxicity due to the inhibition of acetylcholinesterase (AChE). In recent years, 
however, an increasing number of in vivo studies indicate that OP insecticides, and 
particularly the extensively used organophosphorothionates chlorpyrifos (CP) and 
diazinon (DZ), can also cause developmental neurotoxicity [2, 3]. This toxicity is related 
to the ability of these OPs to interfere with a number of neurodevelopmental events 
including the process of neuronal differentiation and axon formation [4, 5].  
 
Phosphorothionates are known to be metabolically converted in vivo to their 
desulphurated, oxon analogues by specific mixed function oxidases (cytochrome p450s), 
mainly in the liver [6]. In vitro studies using a variety of cell culture systems demonstrate 
that the oxon metabolites of both CP and DZ have the capacity to directly disrupt the 
process of neurite outgrowth, a widely employed marker of neuronal differentiation in 
vitro. Thus, the oxon metabolite of CP, chlorpyrifos oxon (CPO) inhibits the outgrowth 
of axonal processes in primary cultures of embryonic rat superior cervical [7] and dorsal 
root [8] ganglia neurons. CPO can also impair the extension of neurites in the rat PC12 
pheochromocytoma [9] and mouse N2a neuroblastoma [10] cell lines. The ability to 
disrupt the process of neurite development in the N2a cell line is also exhibited by the 
oxon metabolite of DZ, diazoxon (diazoxon, DZO).  
 
The neuronal cytoskeleton, and in particular microtubules (MTs) and neurofilaments 
(NFs), is one of the most important endogenous factors that control normal 
neurodevelopment including the process of axonal/neurite outgrowth [11]. This study 
sought to assess in differentiating mouse N2a neuroblastoma cells the effects of DZO on 
the expression and distribution of a number of MT and NF proteins which are 
neurodevelopmentally important and may be involved in neurite outgrowth and stability. 
DZO was employed at three different concentrations, 1, 5 and 10 μM, which were found 
to cause extensive impairment of neurite outgrowth. These DZO concentrations were 
previously shown to be non-cytotoxic in our laboratory using the same differentiating cell 
line [12].  
 
Materials and methods 
 
Materials. The mouse neuroblastoma cell line was obtained from ICN (Thane, UK). Cell 
culture plastic materials were supplied by Scientific Laboratory Supplies (Nottingham, 
UK). Cell culture reagents, as well as mouse monoclonal antibodies to total α-tubulin 
(B512), total β-tubulin (TUB 2.1), β III-tubulin (SDL.3D10) and polyglutamylated 
tubulin (clone B3) were purchased from Sigma-Aldrich Co. Ltd (Poole, UK). Mouse 
monoclonal antibody to glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sc-32233), 
rabbit polyclonal antibody against MAP 1B (H-130; sc-25729) and goat polyclonal 
antibodies against tau (C17; sc-1995), NFL (N-14; sc-12966) and NFM (G-20; sc-16143) 
were obtained from Santa Cruz Biotechnology (CA, USA). Anti-phosphorylated NFH 
mouse monoclonal antibody SMI34 was supplied by Sternberger Monoclonals Inc. 
(Berkeley, USA). Horseradish peroxidase (HRP)-conjugated anti-mouse, anti-rabbit and 
anti-goat secondary antibodies were bought from DakoCytomation (Ely, UK). 
Fluorescein isothiocyanate (FITC)-conjugated goat anti rabbit immunoglobulin and 
tetramethyl rhodamine isothiocyanate (TRITC)-conjugated rabbit anti-mouse 
immunoglobulin were also purchased from DakoCytomation. Diazoxon (purity 97.6 %) 
was supplied by Chem Service Inc. (West Chester, PA, USA). All other chemicals and 
reagents were the best grade available from Sigma-Aldrich Co. Ltd (Poole, UK).  
 
Growth and maintenance of N2a cells. N2a cells were maintained as monolayers in the 
logarithmic phase of growth at 37
o
C in a humidified atmosphere of 5% CO2 and 95% air 
employing growth medium comprising Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% v/v foetal calf serum, 1 mM glutamine, penicillin G (100 U/ml) 
and streptomycin (100 μg/ml), as described previously [14, 15] and sub-cultured at 60-
80% confluence.  
  Induction of N2a cell differentiation and DZO treatment. N2a cells, between passage 10 
and 20, were detached by pipette and harvested by centrifugation. Cell pellets were 
resuspended in 1 ml growth medium and cell number determined in a haemocytometer 
chamber. For determination of neurite outgrowth, N2a cells, detached at 60-80% 
confluence, were plated out in 24-well culture dishes at a density of 5x10
4
 cells/ml, with 
each well receiving 0.5 ml of cell suspension. The cells were allowed to recover for 24 h 
in a CO2 incubator and then, to induce differentiation, the growth medium was carefully 
withdrawn and replaced with serum-free medium containing 0.3 mM dibutyryl cAMP 
and with or without DZO. Cells were returned to the incubator and allowed to 
differentiate for 24 h. DZO was freshly prepared as 200-fold concentrated stock solutions 
in dimethyl sulphoxide (DMSO) and added to the serum-free medium. The final DMSO 
concentration in the medium of DZO-treated and untreated control cells was 0.5% v/v. In 
the present study, DZO was employed at final concentrations of 1, 5 and 10 μM. These 
concentrations have been previously shown to non-cytotoxic towards the differentiating 
N2a cells, as determined by two different cell viability assays [12]. 
 
 Assessment of neurite outgrowth. Following differentiation for 24 h, N2a cell 
monolayers were fixed with 90% methanol in Tris-buffered saline (TBS; 10 mM Tris, 
140 mM NaCl, pH 7.4) and stained with Coomassie Brilliant Blue R-250. They were then 
washed with TBS and viewed with the aid of an inverted light microscope [14]. 
Alternatively, they were stained with anti-tubulin or anti-NFH antibodies as described 
below. From each well, five randomly selected fields giving a total cell count of 200-300 
cells/well were examined. In each well the total number of cells and the total number of 
axon-like processes were counted and the mean number of axon-like processes per 100 
cells was calculated. An axon-like process was defined as an extension with a length 
greater than two cell body diameters [16]. 
 
 
Gel electrophoresis and Western blotting. For Western blotting analysis, N2a cells were 
seeded in T25 culture flasks in a volume of 10 ml growth medium at a density of 
5x10
4
/ml. They were then induced to differentiate in the absence or presence of 1, 5 or 10 
μM DZO, as described above. At the end of the differentiation period and prior to cell 
lysis samples were checked microscopically for proper neurite development (untreated 
control cells) and neurite outgrowth inhibition (DZO-treated cells). Intact cell monolayers 
were then solubilised by boiling in 1 ml electrophoresis sample buffer containing 62.5 
mM Tris, 2% w/v sodium dodecyl sulphate (SDS), 10% w/v β-mercaptoethanol and 
0.002% w/v bromophenol blue. The resultant cell lysates were subsequently subjected to 
gel electrophoresis in the presence of sodium dodecyl sulphate (SDS/PAGE) employing 
either a 7.5% w/v or a 10% w/v polyacrylamide resolving gel, as appropriate, overlaid 
with a 4% w/v stacking gel [17]. Separated proteins were then transferred 
electrophoretically onto nitrocellulose membrane filters [18]. The resultant Western blots 
were checked for equal protein loading and efficient transfer by staining with 0.05% w/v 
copper pthalocyanine [19] and were then blocked with 3% w/v non-fat milk powder 
(Marvel) in phosphate-buffered saline (Marvel/PBS) containing 0.05% w/v Tween-20 for 
at least 1 h at room temperature. The blots were then probed overnight at 4
o
C with 
appropriate dilutions of primary antibodies in Marvel/PBS. The antibodies included the 
mouse anti-total β-tubulin (dilution 1:1000), mouse anti-β-tubulin III (1:1000), anti-
polyglutamylated tubulin, rabbit anti-MAP1B (1:200), goat polyclonal anti-tau (dilution 
1:500), goat anti-NFL (dilution 1:200), goat anti-NFM (1:100) and anti-GAPDH (1:1000). 
Following six 10-min washes with PBS containing 0.05% w/v Tween 20 (PBS/Tween), 
the blots were probed with appropriate dilutions of HRP-conjugated anti-mouse, anti-
rabbit or anti-goat secondary antibodies for 3 h at room temperature. After six further 
washes with PBS/Tween, antibody reactivity was visualised with enhanced 
chemiluminescence reagent (ECL). For quantification of antibody reactivity, 
densitometric scanning of images from probed Western blots was performed by using the 
Quantiscan image analysis system (Version 3; Biosoft), as described previously [19]. The 
band densities for total β-tubulin, βIII-tubulin, polyglutamylated tubulin, MAP 1B, tau, 
NFL and NFM were normalised to band densities for GAPDH. 
 
Indirect immunofluorescence staining of N2a cell monolayers. For this, 200 µl of cell 
suspension at 10
4 
cells/ml were seeded into cell culture chamber slides. Following 
recovery, cells were induced to differentiate for 24 h in the absence and presence of 10 
µM DZO, after which cell monolayers were fixed for 10 min at -20ºC in 90% methanol 
in PBS, blocked and incubated with either anti-α-tubulin, anti-βIII-tubulin, anti-MAP 1B 
or anti-phosphorylated NFH (all diluted at 1:200 in 3 % w/v BSA in PBS) and either 
FITC- or TRITC-conjugated secondary antibodies (diluted 1:100 in 3% w/v BSA in PBS) 
as described previously [20], except that the anti-fade mountant contained the nuclear 
staining agent  DAPI (Vector Laboratories Inc.) 
 
Statistical analysis. Quantitative data were expressed as mean ± SEM for at least 3 
independent experiments. Statistical analysis for multiple comparisons was performed 
using one way ANOVA with a post-hoc Tukey test, using 95 % confidence limits. 
Otherwise the Mann Whitney U-test was employed. 
 
3. Results 
 
Preliminary experiments showed that exposure for 24 h to DZO concentrations of 1, 5 
and 10 μM used in this study produced approximately 50 – 75 % inhibition of neurite 
outgrowth (data not shown), which was similar to earlier data [12]. This was further 
confirmed by measurement of axon-like processes in cells stained with antibodies to total 
α-tubulin and phosphorylated NFH (Fig 1).  
 
In order to reveal the nature of the biochemical phenomena that underlie these potent 
effects of DZO on cell morphology, Western blots of extracts of N2a cells exposed to the 
above oxon concentrations for 24 h were probed with a number of antibodies that are 
known to recognise key proteins of the neuronal cytoskeleton, since the latter is important 
in cell morphology and the process of neurite outgrowth. As can be seen in the probed 
blots in fig. 2, the cross-reactivity of N2a cell lysates with a monoclonal antibody that 
recognises total β-tubulin was apparently unaffected by treatment with DZO, at all 
concentrations employed. In contrast, probing of these blots with a monoclonal antibody 
that recognises specifically isotype III of β-tubulin revealed that extracts of N2a cells that 
had been exposed to higher concentrations of DZO exhibited decreased cross-reactivity 
compared to untreated controls. On the other hand, cross-reactivity with an antibody  
 Fig. 1. Effects of diazoxon on neurite outgrowth. N2a cells were induced to differentiate in the 
absence (control) and presence of 10 µM DZO , stained with antibodies to total α-tubulin (B512) and 
phosphorylated NFH (SMI34) and assessed for neurite outgrowth as described in Materials and 
methods. Shown are mean numbers of axon like neurites per 100 cells ± S.E.M. Asterisks indicate 
significant differences compared to the corresponding control (p<0.05). 
 
recognising polyglutamylated tubulin seemed to be unchanged following DZO treatment. 
By contrast, cross-reactivity of blots with an antibody recognising MAP 1B appeared to 
be reduced in DZO-treated cells compared to controls. On the other hand, exposure of 
N2a cells to all DZO concentrations for 24 h had no apparent effect on the levels of 
cross-reactivity with an antibody recognising tau protein. Finally, probing of blots with 
antibodies recognising the NF proteins NFL and NFM demonstrated no apparent 
differences in cross-reactivity between DZO treated samples and controls (data not 
shown).  
 
Quantification of the observed alterations in antibody reactivity was subsequently carried 
out employing Quantiscan image analysis software. Densitometric analysis confirmed the  
 Fig. 2. Western blotting analysis of proteins in control and DZO-treated cell extracts. N2a cells were 
induced to differentiate for 24 h in the absence or presence of 1, 5 and 10 μM DZO prior to extraction of 
the cell monolayers. Proteins were then separated by SDS-PAGE, subjected to Western blotting and the 
resultant blots probed with monoclonal antibodies against total β-tubulin, βIII-tubulin and MAP1B, as 
described in Materials and methods. Shown are representative digital images taken using the FUJIFILM 
LAS-3000 ECL camera. Blots probed with antibodies against the two neurofilament proteins for which the 
densitometric analysis demonstrated no changes, are not shown. 
 
lack of statistically significant changes in the levels of total β-tubulin, polyglutamylated 
tubulin and tau (table 1) as well as in those of NFL and NFM (not shown) following 
treatment of N2a cells with 1-10 μM DZO. In contrast, the quantitative analysis revealed 
that exposure of differentiating N2a cells to 10 μM DZO for 24 h caused a statistically 
significant 38.6 percent reduction in the levels of the βIII-tubulin isotype, whereas a 
reduction of 23.6 percent induced by 5 μM DZO was not statistically significant. 
Densitometric analysis also demonstrated that treatment of N2a cells for 24 h with 10 μM  
 
 
 
 
 
 Antigen 
 
 
 
Densitometric peak area 
(% Control ± S.E.M.) 
 
 
  
1 µM DZO 
 
 
5 µM DZO 
 
10 µM DZO 
 
 
Total β-tubulin 
 
 
98.410.9 
 
114.84.7 
 
99.05.2 
 
βIII-tubulin 
 
 
114.99.1 
 
 
76.49.7 
 
61.413.1* 
 
Polyglutamylated 
tubulin 
 
107.0±22.3 
 
90.2±23.1 
 
90.6±24.7 
 
MAP 1B 
 
 
76.012.6 
 
 
75.013.4 
 
51.312.5* 
 
Tau 
 
 
149.2±56.9 
 
129.7±61.5 
 
133.3±14.1 
Table 1. Densitometric analysis of antibody reactivity on Western blots. 
Immunoblots probed with antibodies against total β-tubulin, β-III tubulin, polyglutamylated tubulin, 
MAP1B and tau were incubated with Luminol reagent and the resultant enhanced chemiluminescence was 
detected as described in Materials and methods. Band densities for all proteins above were normalised to 
band densities for glyceraldehyde-3-phosphate dehydrogenase. Values are expressed as a percentage of 
their corresponding control ± S.E.M. for 3 or 4 independent experiments, each experiment involving a 
different initial cell population. Asterisks indicate values that were significantly different from their 
corresponding controls (*p<0.05).  
 
DZO resulted in a statistically significant 48.7 percent decrease in the levels of MAP 1B, 
whereas 1 and 5 μM DZO produced slight but not statistically significant decreases of 24 
and 25 percent, respectively. 
        
As shown in fig. 3, indirect immunofluorescence staining with monoclonal antibodies 
B512 and SMI34 showed that there were less axon-like outgrowths in DZO treated cells 
than in control cells (see also fig. 1). Furthermore, the intensity of antibody staining in 
neurites and cell bodies was relatively weak in DZO treated cells compared to the control 
for anti-βIII-tubulin but not for anti-α-tubulin, with evidence of aggregation in the former. 
Fewer neurites were also detectable in DZO treated cells stained with anti-MAP1B, 
although the staining intensity was very weak even in control cells (not shown). Staining 
with the anti-phosphorylated NFH antibody SMI34 also confirmed the appearance of cell 
body aggregate staining in DZO treated cells, indicative of neurofilament disruption.  
 
Discussion 
 
The densitometric data obtained in this study indicate that concentrations of DZO which 
severely impair neurite outgrowth in N2a cells have no effect on the levels of total β-
tubulin. The fact that total α-tubulin levels are also unaffected under identical conditions 
[12] suggests that DZO exposure has no effect on the overall levels of α and β subunits. 
A similar lack of effect was observed on total α-tubulin following exposure of 
differentiating N2a cells to the parent compound DZ [20]. 
 
However, β-tubulin exists as a number of distinct isotypes [21], of which class III β-
tubulin (βIII-tubulin) is the only one that is present almost exclusively in neuronal cells 
[22] and is one of the earliest neuronal cytoskeletal proteins to be expressed during 
development [23,24]. Western blotting analysis of this β-tubulin isotype in particular 
revealed that, in contrast to the lack of its effect on total β-tubulin, DZO, at a neurite-
inhibitory dose of 10 μM, induced a significant reduction in the levels of βIII-tubulin. 
 
These data suggest that this effect is specific for βIII-tubulin since the monoclonal 
antibody employed for the analysis is known to recognise specifically an epitope located 
on this isoform and not to cross-react with other tubulin isotypes [25]. The observation of 
decreased βIII-tubulin levels at a DZO concentration that has been shown in this study to 
severely impair neurite outgrowth in N2a cells is consistent with the findings of studies in 
other laboratories showing that synthesis of the βIII-tubulin isotype is crucially involved 
in microtubule formation during neuritogenesis in vivo and in differentiating mouse 
neuroblastoma cells [22, 26].  
 
 Fig. 3. Indirect immunofluorescence staining of N2a cells induced to differentiate in the absence and 
presence of DZO. N2a cells were induced to differentiate for 24 h in the absence (a, c, e) and presence (b, 
d, f) of 10 μM DZO prior to indirect immunofluorescence staining of the cell monolayers as described in 
Materials and methods. Shown are typical images of staining with anti-α-tubulin (a, b), anti-βIII-tubulin (c, 
d) and anti-phosphorylated NFH (e, f). Horizontal arrows indicate typical neurites. Downward vertical 
arrows indicate aggregated staining in cell bodies. Bar represents 20 µm. 
 
Reduced levels of βIII-tubulin could reflect increased degradation by proteases such as 
calpain, which has been shown to be activated in response to OP treatment in vivo [27]. 
Alternatively, the reduction in βIII-tubulin levels could be due to decreased synthesis, as 
phosphorothionates are known to inhibit the synthesis of both DNA and proteins in vivo 
[28]. The lack of a significant change in the total levels of β-tubulin in N2a cells treated 
with 10 μM DZO despite a significant reduction in the levels of the βIII-tubulin isotype 
can be attributed to the fact that there is a total of five different β-tubulin isotypes in 
differentiating mouse neuroblastoma cells [26] and that in these cells the βIII-tubulin is 
not the main isotype present [29]. 
 
Immunoblot analysis also indicated that DZO exposure reduces the levels of the MT 
stabilising protein MAP 1B. Similarly to βIII-tubulin, MAP 1B is not uniquely present in 
the nervous system but is more abundantly expressed in neurons, especially during 
development [30]. It is the first MAP to be expressed in neurons [31] and plays a key role 
in neuronal differentiation and the early stages of neuritogenesis [32] when it can act 
concomitantly or in coordination with βIII-tubulin [22]. Our present findings showing 
that doses of DZO which cause neurite inhibition, apart from decreasing the levels of 
βIII-tubulin, also reduce at the same time the levels of MAP 1B are consistent with the 
above data. On the other hand, the fact that the levels of another MAP, tau, were not 
affected by neurite inhibitory concentrations of DZO, is in line with previous data 
showing that the retraction of neurites in neuroblastoma cells is not necessarily linked to 
changes in the amount of tau [33]. 
 
Tubulin (poly)glutamylation is a posttranslational modification which is important for 
binding of tau and other MAPs to tubulin [34]. Glutamylated tubulin accumulates in 
neuronal cultures and brain during development and may have a role in neurite outgrowth. 
However, the results suggest that the neurite inhibitory doses of DZO used in this study 
had no significant effect on the glutamylation state of tubulin. It is worth noting that the 
level of α-tubulin tyrosination, another posttranslational modification of tubulin linked to 
microtubule stability, was also found to be unaffected in N2a cells by DZO treatment 
[12].  
 The reduced numbers of long neurites in immunofluorescently stained DZO treated cells 
confirms our finding that 10 µM DZO causes profound inhibition of neurite development, 
as shown in the morphological analysis presented in fig. 1. However, the reduced 
intensity of staining of those neurites present with antibodies to βIII-tubulin but not total 
α-tubulin, suggested a redistribution of βIII-tubulin. Reduced levels of these proteins in 
developing neurites may be a key factor in the inhibition of neurite outgrowth by DZO.  
 
In contrast to the considerable changes that DZO induces in the levels of two 
neurodevelopmentally relevant proteins of the MT system, the effects of this compound 
on the levels of NFL and NFM, two proteins of the NF network, were not significant. The 
protein levels of NFH, whose expression in growing neurites occurs later than that of 
NFL and NFM [11] has also been found to be unaffected by DZO treatment under 
identical conditions [12]. On the other hand, since the phosphorylation of NFs is an 
important factor in the regulation of their known ability to modulate axon girth and 
axon/neurite stabilisation [35], the possibility of neurite-inhibitory doses of DZO exerting 
a significant effect on NFL and NFM phosphorylation cannot be precluded, particularly 
in view of our previous data showing that DZO under identical conditions affects the 
phosphorylation of NFH [12]. Indeed, in the current study, immunofluorescence staining 
of cells with monoclonal antibody SMI34 (which recognises phosphorylated NFH) 
confirmed that there was a major redistribution of this network in N2a cells treated with 
10 µM DZO. This finding is in good agreement with previous studies using the parent 
compound DZ [20] and suggests that either reduced levels of NFH or its altered 
phosphorylation status may be associated with pesticide induced disruption of the NF 
network. 
 
The significant effects of DZO on the levels of βIII-tubulin and MAP 1B are caused by a 
sub-cytotoxic concentration of 10 μM and such changes in two neurodevelopmentally 
important cytoskeletal proteins may be a primary cause of the inhibition of neurite 
outgrowth induced in N2a cells. On the other hand, DZO concentrations of 1 and 5 μM 
have no significant effect on the above two proteins, although they produce considerable 
neurite outgrowth impairment. Neurite inhibition by these concentrations of DZO in N2a 
cells has been previously shown to be associated with significant alterations in the levels 
of the axon growth associated protein GAP-43 and the extent of NFH phosphorylation 
[12]. 
 
Comparison of the effects of DZO with those of its parent phosphorothionate DZ shows 
that the pattern of cytoskeletal changes related to neurite inhibition is not identical for the 
two compounds. For example, exposure to both DZ [20] and DZO decreases the levels of 
MAP 1B in N2a cells. Furthermore, both compounds impair neurite outgrowth without 
inducing any change in the levels of total α-tubulin [12, 20]. On the other hand, in 
contrast to DZ, which has been shown to have no effect on the developmentally relevant 
βIII-tubulin isotype in N2a cells [36], DZO induces a significant reduction in the levels of 
this protein, in line with a number of studies indicating a greater range and/or potency of 
neurodevelopmental effects of the oxon metabolites compared to their parent 
phosphorothionates [13]. The difference between DZ and DZO is also extended to their 
effects on proteins of the NF network, as our previous N2a data indicate distinct actions 
of neurite-inhibitory doses of the two compounds on the levels and phosphorylation of 
NFH [12, 20]. Moreover, the differential effects of DZ and DZO on cytoskeletal proteins 
are not confined to differentiating N2a cells, but also occur in differentiating cultured 
cells of glial origin [20, 37]. Thus the greater potency of DZO to inhibit neurite 
outgrowth in differentiating neuronal cells [12,20] may be related to its ability to disrupt 
additional cytoskeletal protein targets to those affected by DZ. 
 
The above morphological and biochemical effects of DZO noted in vitro are induced by 
concentrations similar to those likely to occur in vivo in the developing organism. For 
example, in a prospective cohort study with randomised sampling, one third of foetal 
meconium samples contained detectable amounts of diazinon with a median value of 
12.96 µg/ml, which is the equivalent of approximately 40 µM [45]. Although studies 
have not been conducted specifically with DZO, toxicokinetic data obtained for CPO 
indicate that oxon metabolite levels in the low micromolar range are attainable in the 
developing human [13]. Therefore the above mentioned DZO-specific cytoskeletal 
changes are relevant to developmental  toxicity in humans. 
 
DZO and oxon metabolites in general have a considerably higher aqueous solubility 
compared to their parent phosphorothionates [38] which could potentially affect their 
penetration into the foetus. However, data showing significant inhibition of 
cholinesterase in foetal tissues after in vivo administration of phosphorothionate 
insecticides [39] indicate that exposure of the foetus to the oxon occurs. In humans, it is 
thought that the foetus is mainly exposed to oxons formed in maternal tissues. On the 
other hand, placental metabolism is unlikely to contribute significantly to oxon formation, 
since CYP2B6, the main CYP responsible for oxon generation in humans [40, 41], is 
expressed to a limited extent in human placenta [42]. However, although relatively low 
levels of CYP2B6 are found in the human foetus compared to later developmental stages 
[43], the levels of the OP degrading enzyme paraoxonase 1 (PON1) are also very low 
[44] during early development, which could allow some conversion of CPF to CPO 
within the foetus and/or for  the oxon metabolite to accumulate. Additionally, 
polymorphisms in specific coding and regulatory sequences of the PON1 gene are a 
major cause of reduced serum PON1 activity and would result in increased risk of 
susceptibility to the toxicity of the oxon metabolite [44]. 
 
In summary, the results of this study indicate that exposure of differentiating cultured 
cells of neuronal origin to the oxon metabolite of the insecticide DZ causes significant 
reductions in the levels and distribution specifically of βIII-tubulin and MAP 1B, two 
proteins of the MT network that are known to be important for axonogenesis. These 
effects are induced by concentrations of DZO which are sub-cytotoxic and 
toxicologically relevant and they are not related to acetylcholinesterase inhibition [12]. 
Certain effects produced by DZO are not seen with its parent phosphorothionate DZ. 
Taken together with our other findings in differentiating C6 cells [37], the present data 
imply differential targeting by DZO and DZ of key cytoskeletal proteins during neuronal 
and glial cell differentiation and indicate that the oxon metabolite may contribute 
significantly to the developmental neurotoxicity produced following exposure of the 
developing organism to the insecticide.    
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